NCT05335473 2023-04-06
Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure
Henan Cancer Hospital
Phase 1/2 Unknown
Clinical Trials
1 trialsHR Positive HER2 Negative Advanced Breast Cancer × N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide × Clear all